AU Patent

AU1781601A — 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors

Assigned to SmithKline Beecham Corp · Expires 2001-06-04 · 25y expired

What this patent protects

Novel substituted quinazoline compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.

USPTO Abstract

Novel substituted quinazoline compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.

Drugs covered by this patent

nintedanib-esylate (NINTEDANIB ESYLATE)

Patent Metadata

Patent number: AU1781601A
Jurisdiction: AU
Classification: —
Expires: 2001-06-04
Drug substance claim: No
Drug product claim: No
Assignee: SmithKline Beecham Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.